Onesource Specialty Pharma

Onesource Specialty Pharma Debt-to-Equity

The Debt-to-Equity Ratio of Onesource Specialty Pharma (ONESOURCE.NS) as of Oct 31, 2026 is 0.26. In the previous year, Debt-to-Equity Ratio was 0.16 — a change of 60.93% (higher).

Debt-to-Equity

0.26

YoY

60.93%

Last updated:

Debt-to-Equity Ratio of Onesource Specialty Pharma is 2026 0.26 . Debt-to-Equity Ratio of Onesource Specialty Pharma was 2025 0.16 . It decreases by 60.93% higher compared to the previous year.

The Onesource Specialty Pharma Debt-to-Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt-to-Equity
Date
Debt-to-Equity
Jan 1, 2023
0.43 INR
Jan 1, 2024
0.69 INR
Jan 1, 2025
0.16 INR
Jan 1, 2026
0.26 INR
The Onesource Specialty Pharma Debt-to-Equity history
YEARDebt-to-EquityYoY
0.26+60.93%
0.16-76.65%
0.69+60.98%
0.43—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Onesource Specialty Pharma Stock analysis

What does Onesource Specialty Pharma do? Onesource Specialty Pharma Ltd operates as a specialty pharma pure-play contract development and manufacturing organization (CDMO) within the Life Sciences Tools & Services industry. Based in Bangalore, Karnataka, the India-based company provides vertically integrated biopharma services, focusing on the development and manufacture of complex biologics, biosimilars, and vaccines. Its core offerings include prefilled syringes with or without safety devices, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors. The firm supports the development of complex biologics such as microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and ribonucleic acid (RNA) products. The company generates revenue by catering to a variety of capsule shapes and sizes through its integrated services. These services encompass formulations ranging from traditional softgels to enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and su. By providing comprehensive biologics solutions, the firm serves clients requiring advanced manufacturing capabilities for diverse pharmaceutical delivery systems and therapeutic modalities. Onesource Specialty Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Onesource Specialty Pharma stock

Debt-to-Equity Ratio of Onesource Specialty Pharma is 0.26 in 2026.

Debt-to-Equity Ratio of Onesource Specialty Pharma changed from 0.16 to 0.26, representing a 60.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt-to-Equity Ratio Onesource Specialty Pharma since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Equity ratio measures financial leverage by comparing total debt to shareholders' equity. Higher ratios indicate more debt financing relative to equity.

Debt/Equity = Total Debt / Shareholders' Equity

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Equity Ratio's Onesource Specialty Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Onesource Specialty Pharma

All Key Metrics — Onesource Specialty Pharma